ThromboGenics and BioInvent Announce Alliance with Roche

Exploring Burnout Causes and Management in Oncologic Practice

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Eric P. Winer, MD

June 2nd 2025

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Ashling Wahner

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Silas Inman

Daratumumab Plus KRd May Be a New SOC Option in NDMM

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.

Related Content

Exploring Burnout Causes and Management in Oncologic Practice

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Eric P. Winer, MD

June 2nd 2025

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Ashling Wahner

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD

May 26th 2025

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Silas Inman

Daratumumab Plus KRd May Be a New SOC Option in NDMM

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.